Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivoceranib - HLB

Drug Profile

Rivoceranib - HLB

Alternative Names: Aitan; Apatinib; Apatinib mesylate; Apatinib Mesylate Tablets; YN-968-D1

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advenchen Laboratories LLC
  • Developer Elevar Therapeutics; Henan Cancer Hospital; Hunan Cancer Hospital; Jiangsu Hengrui Medicine Co.; Peking University
  • Class Amides; Antineoplastics; Cyclopentanes; Nitriles; Pyridines; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Adenoid cystic carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • Phase III Fallopian tube cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Adenoid cystic carcinoma; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Lung cancer; Malignant melanoma; Osteosarcoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Uterine cancer
  • Phase I Oesophageal cancer

Most Recent Events

  • 01 Oct 2021 Biomarkers information updated
  • 30 Jun 2021 The First Affiliated Hospital with Nanjing Medical University in collaboration with Jiangsu Hengrui Pharmaceutical completes a phase II trial for Liver cancer (Combination therapy, Neoadjuvant therapy, First-line therapy) in China (PO) (NCT04297202)
  • 08 Jun 2021 Jiangsu HengRui Medicine completes a phase II RESCUE trial in Liver cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in China (IV) (NCT03463876)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top